Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2093 | LY3819253 Wiki | 0.41 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The novel COronaVIrus Disease 19 (COVID-19) outbreak has impacted daily activities in nearly 210 countries and territories worldwide. In Ecuador, the city of Guayaquil has nearly two-thirds of the COVID-positive patients in the country and nearly 40% of infected individuals are health-care related personnel. Nonemergent, emergent and urgent endoscopic procedures are necessary to be performed during the COVID-19 pandemic. Several experiences in the management of the endoscopic unit during the pandemic has been proposed. We aimed to prospectively evaluate a strict protocol for preventing potential nosocomial infection of COVID-19.
Description: COVID-19 infection in the staff documented via PCR
Measure: Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study. Time: through study completion, an average of 30 daysDescription: Endoscopic records of patients treated during the COVID-19 protocol
Measure: Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study. Time: through study completion, an average 30 daysDescription: technical success of endoscopic procedures
Measure: Technical success rate of endoscopic procedures during the 30-days study period. Time: through study completion, an average 30 daysDescription: serum levels of IgG and IgM against COVID-19
Measure: IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study. Time: through study completion, an average 30 daysDescription: adverse events of endoscopic procedures
Measure: Adverse events rate of endoscopic procedures during the 30-days Time: through study completion, an average 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports